Thus, surrogate endpoints like response rate and progression-free survival are commonly accepted, although all parties involved realize the risk involved.
因此，替代终点如反应率和无进展生存率被普遍接受，尽管各方意识到风险所在。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
The primary end point was progression-free survival; secondary end points included the objective response rate, overall survival, and safety.
主要研究终点为无进展生存（PFS），次级研究终点包括客观有效率、总生存和安全性。
The primary end point was progression-free survival; secondary end points included the objective response rate, overall survival, and safety.
主要研究终点为无进展生存（PFS），次级研究终点包括客观有效率、总生存和安全性。
应用推荐